Health Care Equipment & Services

Dexcom’s recent insider sale shows routine liquidity management, not a bearish signal—focus on the company’s product pipeline and buy‑back plans for growth.

Centene insider sale: CEO Tanyá McNally sells 964 shares after a 12% monthly rise—signals leadership confidence amid rising market, ESG initiatives, and future growth prospects.

Avanos Medical’s CEO sells shares amid a $1.3 billion AIP acquisition: insider moves, valuation impacts, and future infection‑prevention & pain‑management growth prospects.

CEO’s Clover Health sale sparks investor curiosity—learn why the routine trade matters, how new women’s health plans could boost value, and what it means for clinicians and shareholders.

DiBella’s 10b5‑1 sale of 1,000 Simulations Plus shares shows no ownership shift but signals exec confidence, hinting at upcoming partnerships and AI‑driven drug‑simulation gains.

Insider buying at Inspire Medical Systems shows board confidence amid market lows, revealing a disciplined, long‑term investment strategy for a niche neurostimulation firm.

Sanara Medtech insider sales post‑product launch reveal mixed confidence in short‑term valuation – a nuanced look at tax‑withholding trades, regulatory rules and market dynamics.

Insightful analysis of ASHS insider RSU grant and its bullish impact on future growth, tech‑enabled operating rooms, and insurance services.

CEO Paul Gudonis’s recent insider buying of Myomo shares signals confidence but the company’s weak earnings and medical‑robotics niche still pose risks.

CEO Paul Gudonis’s recent RSU purchase boosts optimism for Myomo’s exoskeleton growth, signaling insider confidence and potential upside despite a negative P/E.